Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

Annemiek Broijl, Marie-Jose Kersten, Wendimagegn Ghidey Alemayehu, Mark-David Levin, Okke de Weerdt, Edo Vellenga, Ellen Meijer, Shulamit Wittebol, Bea C. Tanis, Petra B. Cornelisse, Marian Stevens-Kroef, Gerard M. J. Bos, Pierre W. Wijermans, Henk Lokhorst, Pieter Sonneveld

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numbere149
JournalHaematologica-the Hematology Journal
Volume101
Issue number4
DOIs
Publication statusPublished - Apr 2016

Keywords

  • escalated dose
  • VRD
  • first relapse
  • multiple myeloma

Cite this

Broijl, A., Kersten, M-J., Alemayehu, W. G., Levin, M-D., de Weerdt, O., Vellenga, E., Meijer, E., Wittebol, S., Tanis, B. C., Cornelisse, P. B., Stevens-Kroef, M., Bos, G. M. J., Wijermans, P. W., Lokhorst, H., & Sonneveld, P. (2016). Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma. Haematologica-the Hematology Journal, 101(4), [e149]. https://doi.org/10.3324/haematol.2015.132431